Skip to main content Skip to navigation

Licensing Opportunities available from Warwick Ventures

biology logo Chemistry logo Computing logo Engineering logo Medicine logo Physics logo
Biology Chemistry Computing Engineering Medicine Physics

These pages contain details of the technologies currently available to licence from Warwick Ventures.
If you would like more details of any of these technologies, please contact the relevant Business Development
Manager.

New technologies are added regularly, so do please register your interest and we will send through details of
opportunities as they are published. You can also use the RSS feed on the Licensing Opportunities page to
keep up to date.


IVF pre-implantation screening method

image

A team at the University of Warwick has developed a new screening test that potentially provides an accurate and noninvasive method for assessing embryos during IVF treatment, prior to implantation.

More details: IVF pre-implantation screening method

Contact: Dr Suzanna Wood, Business Development Manager, Warwick Ventures. Tel: +44 (0)24 765 75490; email: s.k.wood@warwick.ac.uk

Thu 17 Dec 2015, 11:38 | Tags: Life Sciences and Biotechnology

Increased Epigenetic Variation in Plants

image

A team at the University of Warwick has developed technology to increase the epigenetic variety of plants without the usual undesired side effects. The novel strategy allows a much greater range of epigenetic and phenotypic differences to be introduced than was previously possible.

More details: Increased epigenetic variation in plants

Contact: Dr Suzanna Wood, Business Development Manager, Warwick Ventures. Tel: +44 (0)24 765 75490; email: s.k.wood@warwick.ac.uk

Mon 23 Nov 2015, 16:02 | Tags: Life Sciences and Biotechnology

A novel target and therapeutic leads for the treatment of bovine and human RSV

image

Warwick Ventures has available for licence a patent application covering an entirely novel conserved host cell protein target for the treatment of bovine and human RSV. Promising proof-of-concept studies have demonstrated significant anti-viral activity with a number of chemical lead compounds which are suitable for entry into a drug discovery program.

More details: A novel target and therapeutic leads for the treatment of bovine and human RSV

Contact: Andrew Lee, Business Development Manager, Warwick Ventures. Tel: +44 (0)24 765 75745; email: L.Lane@warwick.ac.uk

Tue 22 Jul 2014, 15:39 | Tags: Life Sciences and Biotechnology